Morgan Stanley Eiger Bio Pharmaceuticals, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.21 - $0.43 $2,900 - $5,939	13,812 New	13,812 $3,000
Q4 2023 Feb 13, 2024	SELL	$0.21 - $0.43 $3,294 - $6,744	-15,686 Reduced 53.18%	13,812 $3,000
Q3 2023 Nov 15, 2023	SELL	$0.28 - $0.93 $8,733 - $29,006	-31,190 Reduced 51.39%	29,498 $8,000
Q2 2023 Aug 14, 2023	SELL	$0.55 - $1.26 $6,991 - $16,015	-12,711 Reduced 17.32%	60,688 $42,000
Q1 2023 May 15, 2023	SELL	$0.89 - $2.52 $672,464 - $1.9 Million	-755,578 Reduced 91.15%	73,399 $66,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $343,934 - $2.52 Million	337,191 Added 68.56%	828,977 $978,000
Q3 2022 Nov 14, 2022	SELL	$6.04 - $9.66 $2.45 Million - $3.92 Million	-405,427 Reduced 45.19%	491,786 $3.7 Million
Q2 2022 Oct 27, 2022	SELL	$4.99 - $8.96 $2.62 Million - $4.7 Million	-525,065 Reduced 36.92%	897,213 $5.65 Million
Q2 2022 Aug 15, 2022	SELL	$4.99 - $8.96 $2.62 Million - $4.7 Million	-525,065 Reduced 36.92%	897,213 $5.65 Million
Q1 2022 Oct 27, 2022	BUY	$3.84 - $9.74 $2.02 Million - $5.11 Million	525,065 Added 58.52%	1,422,278 $11.8 Million
Q1 2022 May 13, 2022	BUY	$3.84 - $9.74 $3.85 Million - $9.76 Million	1,002,129 Added 238.52%	1,422,278 $11.8 Million
Q4 2021 Feb 14, 2022	BUY	$5.12 - $8.19 $1.59 Million - $2.55 Million	310,975 Added 284.84%	420,149 $2.18 Million
Q3 2021 Nov 15, 2021	BUY	$6.68 - $9.1 $729,282 - $993,483	109,174 New	109,174 $730,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.